Tectonic Therapeutic (TECX) Cash & Equivalents (2017 - 2026)

Tectonic Therapeutic (TECX) has 10 years of Cash & Equivalents data on file, last reported at $236.9 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $236.9 million, down 22.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $236.9 million (down 22.65% YoY), and the FY2025 annual result was $253.8 million, up 79.69% from the prior year.
• Cash & Equivalents slipped to $236.9 million in Q1 2026 per TECX's latest filing, from $253.8 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $306.2 million in Q1 2025 and troughed at $6.3 million in Q3 2023.
• A 5-year average of $146.0 million and a median of $141.2 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents plunged 94.54% in 2023, then jumped 2413.35% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $92.6 million in 2022, then sank by 68.92% to $28.8 million in 2023, then surged by 390.94% to $141.2 million in 2024, then jumped by 79.69% to $253.8 million in 2025, then dropped by 6.66% to $236.9 million in 2026.
• Business Quant data shows TECX's Cash & Equivalents at $236.9 million in Q1 2026, $253.8 million in Q4 2025, and $268.4 million in Q3 2025.